SystImmune Presents New Lung Cancer Drug Data at WCLC Congress

SystImmune, Inc. is set to present new global Phase 1 data concerning its drug candidate, iza-bren (izalontamab brengitecan). The presentation will take place at the WCLC Congress 2026, focusing on previously treated patients with EGFR-mutated metastatic non-small cell lung cancer.

The data, gathered from a randomized dose-expansion cohort, reportedly demonstrate promising antitumor activity and a tolerable safety profile. These findings support the selection of the 2.5 mg/kg dose administered on a D1D8 Q3W schedule for further Phase 3 trials.

This research provides insights into the potential efficacy of iza-bren as a targeted therapy for a specific patient population. Such advancements are crucial in the ongoing effort to improve treatment outcomes for non-small cell lung cancer.

SystImmune intends to advance the development of iza-bren following these results, aiming to enhance therapeutic options for patients battling this disease.